1	A pilot study of 0.4% povidone-iodine nasal spray to eradicate
2	SARS-CoV-2 in the nasopharynx
3	Rujipas Sirijatuphat ¹ , Amorn Leelarasamee ^{1,2*} , Thanapat Puangpet ³ , Arunee Thitithanyanont ⁴
4	
5	¹ Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Thanon
6	Wang Lang, Siriraj, Bangkoknoi, Bangkok 10700, Thailand
7	² Faculty of Medicine, Siam University, 38 Petchkasem Rd, Bang Wa, Phasi Charoen, Bangkok
8	10160, Thailand
9	³ Samut Sakhon Hospital, 1500 Ekkachai Rd, Tambon Mahachai, Mueang Samut Sakhon District,
10	Samut Sakhon 74000, Thailand
11	⁴ Department of Microbiology, Faculty of Science, Mahidol University, 272 Rama VI Road,
12	Ratchathewi District, Bangkok 10400, Thailand
13	
14	*Corresponding author:
15	E-mail: amorn.lee@mahidol.ac.th (AL)
16	
17	[¶] These authors contributed equally to this work.
18	Keywords
19	Povidone iodine, nasal spray, COVID-19, SARS-CoV-2, viral eradication, viral culture,
20	nasopharyngeal swab
21	
22	Name of the registry and registration number: Thai Clinical Trials Registry (TCTR) and
23	registration id. TCTR20210125002.

24

25 Abstract

26	We studied the virucidal efficacy of 0.4% povidone-iodine (PVP-I) nasal spray against SARS-
27	CoV-2 in the patients' nasopharynx at 3 minutes and 4 hours after PVP-I exposure. We used an
28	open-label, before and after design, single arm pilot study of adult patients with RT-PCR-
29	confirmed COVID-19 within 24 hours. All patients received three puffs of 0.4% PVP-I nasal
30	spray in each nostril. Nasopharyngeal (NP) swabs were collected before the PVP-I spray
31	(baseline, left NP samples), and at 3 minutes (left and right NP samples) and 4 hours post-PVP-I
32	spray (right NP samples). All swabs were coded to blind assessors and transported to diagnostic
33	laboratory and tested by RT-PCR and cultured to measure the viable SARS-CoV-2 within 24
34	hours after collection. Fourteen patients were enrolled but viable SARS-CoV-2 was cultured
35	from 12 patients (85.7%). The median viral titer at baseline was 3.5 log TCID ₅₀ /mL (IQR 2.8-4.0
36	log TCID ₅₀ /mL). At 3 minutes post-PVP-I spray via the left nostril, viral titers were reduced in 8
37	patients (66.7%). At 3 minutes post-PVP-I, the median viral titer was 3.4 log TCID ₅₀ /mL (IQR
38	1.8-4.4 log TCID ₅₀ /mL) (<i>P</i> =0.162). At 4 hours post-PVP-I spray via the right nostril, 6 of 11
39	patients (54.5%) had either the same or minimal change in viral titers. The median viral titer 3
40	minutes post-PVP-I spray was 2.7 log TCID ₅₀ /mL (IQR 2.0-3.9 log TCID ₅₀ /mL). Four hours
41	post-PVP-I spray the median titer was 2.8 log TCID ₅₀ /mL (IQR 2.2-3.9 log TCID ₅₀ /mL)
42	(P =0.704). No adverse effects of 0.4% PVP-I nasal spray were detected. We concluded that
43	0.4% PVP-I nasal spray demonstrated minimal virucidal efficacy at 3 minutes post-exposure. At
44	4 hours post-exposure, the viral titer was considerably unchanged from baseline in 10 cases. The
45	0.4% PVP-I nasal spray showed poor virucidal activity and is unlikely to reduce transmission of
46	SARS-CoV-2 in prophylaxis use.

47

48 Introduction

49	Coronavirus disease 2019 (COVID-19) is an acute viral respiratory infection caused by
50	the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that emerged in December
51	2019 causing a pandemic that has killed millions [1]. The SARS-CoV-2 can persist in the upper
52	respiratory tract of the patients at least seven days and spreads mainly via droplet and airborne
53	transmission [2]. Patients are infectious for two to three days before the onset of symptoms, and
54	are most contagious one to two days before the patients feel sick [3].
55	Povidone iodine (PVP-I) possesses rapid in-vitro virucidal activity against SARS-CoV-2
56	[4-7]. It can reduce SARS-CoV-2 titers by approximately 100-fold within 30 seconds after PVP-I
57	exposure [5]. It is a broad-spectrum antiseptic and used for topical application in skin solutions
58	and throat sprays [8-10]. PVP-I has a good safety profile and is available in Thailand. We
59	produce 0.4% PVP-I nasal spray and use to spray aerosols into nasal cavities and nasopharynx.
60	The aerosols containing PVP-I will lay down easily on the mucosa in the turbinate and
61	nasopharynx and exert PVP-I virucidal activity onsite. Nasal spray used by ordinary people is
62	easy and more convenient than nasopharynx irrigation which needs to adjust head position and
63	the patients has to hold breathing while performing irrigation to avoid suffocation.
64	We hypothesized that a nasal spray of PVP-I would decrease viable virus titers in the
65	upper airway. One practice guideline advises the use of 0.4% PVP-I nasal application and 0.5%
66	oropharyngeal application to reduce the risk of COVID-19 transmission [11]. However, evidence
67	of in vivo efficacy against SARS-CoV-2 in humans is very limited. Two studies reported that

68 PVP-I administration was associated with decreased SARS-CoV-2 titers in the oral cavity of

69 COVID-19 patients [12,13], while other studies have not demonstrated a virucidal effect of PVP-70 I in humans [14-16].

71 Therefore, we aimed to measure the speed of virucidal activity at three minutes and the 72 sustainability of virucidal action at four hours after administration of a 0.4% PVP-I nasal spray in 73 the patients with laboratory-confirmed COVID-19 infection. If the virucidal effect of PVP-I was 74 rapid and at least 10 fold reduction from baseline was demonstrated in the patients' nasopharynx, 75 it would be beneficial to public and healthcare professionals since PVP-I nasal spray would 76 become a simple and cost-effective measure for preventing cross-contamination and community 77 transmission of SARS-CoV-2. 78 79 **Materials and Methods** 80 This was an open-label, before and after study design, single-arm pilot study conducted 81 from February 15, 2021 to March 15, 2021 at Siriraj Hospital and Samut Sakhon Hospital in 82 Thailand and the patients were followed up for 24 hours in the hospital. The study protocol was 83 approved by the Siriraj Institutional Review Board, Mahidol University, Thailand (COA. 84 408/2020), and by the Ethic Committees of Samut Sakhon Hospital (SKH REC 10/2564/V.1). 85 Written informed consent was obtained from all study participants. This study has been 86 registered at Thai Clinical Trials Registry under registration id. TCTR20210125002. The authors 87 confirmed that all ongoing trials for PVP-I were registered before the patient enrollment. 88 Eligible patients were adults aged 18-60 years with asymptomatic or mild disease due to 89 SARS-CoV-2 with a cycle threshold (Ct) value less than 25 of either the N gene or ORF1ab by 90 reverse transcriptase polymerase chain reaction (RT-PCR) in the 24 hours before study

91 enrollment. Patients with an iodine allergy or thyroid disease, pregnant or lactating women, and 92 patients who had received antiviral agents (i.e., remdesivir and favipiravir) were excluded. 93 The 0.4% PVP-I was made by mixing 10% PVP-I solution with normal saline in 1:30 94 ratio and used as nasal spray. The following intervention was performed sequentially in all 95 patients; 1) specimen collection by nasopharyngeal (NP) swab via the left nostril (pre-exposure 96 specimen), 2) administration of 0.4% PVP-I nasal spray via the left and right nostrils, 3) wait 3 97 minutes and collect NP swab specimens through the left and right nostrils, 4) wait 4 hours and 98 collect an NP swab specimen through the right nostril, 5) all participants were hospitalized to 99 observe symptoms and side effects for at least 24 hours after the PVP-I nasal spray. All NP 100 specimens were assigned numbers to blind laboratory technicians and kept in viral transport 101 media (VTM) at 4 °C and sent to the microbiology laboratory for testing by RT-PCR and viral 102 culture within 24 hours. 103 We planned to demonstrate the rapidity of 0.4% PVP-I antiviral activity by comparing 104 the numbers of viral titer in the left side of nasopharynx (pre-exposure specimen) before and at 3 105 minutes after PVP-I exposure. We also compared the average viral titer in the left side of 106 nasopharynx (pre-exposure specimens) with that of the right side of nasopharynx at 3 minutes

after PVP-I exposure to provide an additional information of virucidal speed assuming that the
viral titers of the left and right sides of nasopharynx were equal before the PVP-I exposure. The
sustainability of antiviral activity was evaluated by comparing the viral titers in the right side of
nasopharynx at 3-minutes and 4-hours after PVP-I exposure.

RNA was extracted from 200 μL of viral transport media from the NP swab samples
using MagDEA® Dx kit (Precision System Science, Chiba, Japan) and SARS-CoV-2 RT-PCR
was performed by amplification of SARS-CoV-2 N and ORF1ab fragments using the Detection

114 Kit for 2019 Novel Coronavirus (2019-nCoV) RNA (PCR-Fluorescence Probing) (Da An Gene 115 Co., Ltd. of Sun Yat-sen University, Guangdong, China), with a cycle threshold ≤ 40 considered 116 positive [17]. For the viral culture test, titers were determined as the 50% tissue culture infective 117 dose (TCID₅₀) of the virus. Vero E6 cells expressing the type II transmembrane serine protease 118 (Vero-TMPRSS2) [18] were seeded into 96-well plates and incubated with a serial dilution of the 119 nasopharyngeal specimen. Cytopathic effects were evaluated daily until a 7-day incubation was 120 completed. 121 Assuming that 70% of the pairs switch from the initial values of viable SARS-CoV-2

counts in cell culture to less than 10 fold after 3 minute of PVP-I nasal exposure and 0% from
the initial value to higher viable viral count after 3 minute of PVP-I nasal exposure, and after
applying continuity correction, the pilot study would require a sample size of 10 pairs to achieve
a power of 80% and a two sided significance of 5% for detecting a difference of -0.70 between
the discordant proportions. [19]

127

128 Statistical analysis

Demographic data were described with descriptive statistics. Quantitative data were described with mean ± standard deviation, or median and interquartile range. Qualitative data were described in frequency (percent). The median of Ct value and viral titers were compared at each time point using the Wilcoxon signed-rank test and Mann-Whitney U test. A p value of </ d>

134

135 Results

Fourteen patients were enrolled and viable culture was obtained from 12 patients
(85.7%). Six patients were male (50%) with a median age 34.0 years (interquartile range (IQR)
27.5-45.0 years). Nine patients had mild disease and three patients had asymptomatic infection.
The median duration from symptom onset to study enrollment was 3.0 days (IQR 1.5-4 days)
(Table 1). No adverse events from PVP-I administration were observed during hospitalization.

ID	Age range	Sex	BMI	Disease severity	Duration from symptom onset to	TCID ₅₀ /mL
	(years)		(kg/m ²)		enrollment (days)	(baseline, left side of nasopharynx)
1	51-55	F	20.7	Mild	3	640
2	26-30	F	25.1	Mild	3	640
3	21-25	М	23.5	Mild	2	40,960
4	46-50	М	19.7	Mild	4	2,560
5	41-45	Μ	22.7	Asymptomatic	NA	10,240
6	41-45	F	20.1	Mild	1	10,240
7	41-45	М	23.5	Asymptomatic	NA	640
8	26-30	F	27.3	Mild	1	2,560
9	21-25	М	24.0	Mild	4	10,240
10	31-35	М	26.0	Asymptomatic	NA	5,120
11	26-30	F	26.4	Mild	3	40,960
12	36-40	F	41.4	Mild	4	640

142Table 1. Demographic data of 12 patients with culturable NP samples

Abbreviations: ID; identification number, F; female, M; male, NA; not applicable,

- 145 TCID₅₀; median tissue culture infectious dose, NP; nasopharyngeal 146
 - 7

147	At 3 minute post-PVP-I nasal spray eight of the 12 patients (66.7%) had a reduction of
148	viral titers. The median viral titer at baseline was 3.5 log TCID ₅₀ /mL (IQR 2.8-4.0 log
149	TCID ₅₀ /mL), and the median viral titer at 3 minute post-PVP-I exposure was 3.4 log TCID ₅₀ /mL
150	(IQR 1.8-4.4 log TCID ₅₀ /mL) (P =0.162) (Tables 2 and 3). A median value of 0.1 log reduction
151	of viable viruses (IQR -0.05-0.23 log reduction) and 75.0% virus reduction (IQR -225.0%-
152	93.8%) were found. The median baseline Ct value of the N gene was 19.84 (IQR 17.77-21.52),
153	whereas the median Ct value of the N gene at 3 minute post-PVP-I was 19.49 (IQR 16.95-23.10)
154	(P=0.569). The median baseline Ct value of the ORF1ab gene was 19.84 (IQR 16.82-22.22), and
155	the median Ct value of the ORF1ab gene at 3 minute post-PVP-I was 19.17 (IQR 15.81-24.87)
156	(<i>P</i> =0.469).

157

ID	N (baseline,	ORF1ab	Ν	ORF1ab	N	ORF1ab	N (4 h,	ORF1ab (4
	Lt)	(baseline, Lt)	(3 min,	(3 min,	(3 min,	(3 min,	Rt)	h, Rt)
			Lt)	Lt)	Rt)	Rt)		
1	21.96	23.00	25.42	26.52	23.44	24.61	21.93	22.91
2	22.64	24.18	23.99	25.45	20.71	22.34	24.47	26.12
3	19.71	21.31	21.54	23.13	19.32	20.62	20.41	21.68
4	20.73	20.14	20.18	21.47	19.79	21.16	19.96	21.29
5	17.73	19.00	18.54	19.83	19.74	21.09	22.23	23.49
6	18.45	19.53	19.23	18.08	18.69	19.87	18.20	19.32
7	20.40	22.52	23.62	26.22	21.49	23.63	21.27	23.10
8	19.96	18.46	19.10	17.72	17.03	15.72	18.21	16.91
9	16.19	15.08	16.42	15.17	17.36	16.29	17.94	16.61

158 Table 2. Cycle threshold (Ct) values for culturable NP samples

10	17.89	16.27	16.39	15.07	15.73	14.50	16.76	15.39
11	16.30	15.20	15.40	14.36	19.41	18.23	16.91	15.83
12	21.78	20.38	19.75	18.51	24.40	23.30	24.68	23.47

¹⁵⁹

Abbreviations: ID; identification number, Lt; left nasopharyngeal samples, Rt; right

- 160 nasopharyngeal samples, NP; nasopharyngeal
- 161
- 162 Table 3. Viral titers for culturable NP samples.

ID	TCID ₅₀ /mL	TCID ₅₀ /mL	TCID ₅₀ /mL	TCID ₅₀ /mL
	(baseline, Lt.)	(3 min, Lt.)	(3 min, Rt.)	(4h, Rt.)
1	640	10	80	160
2	640	40	160	10
3	40960	2560	10240	10240
4	2560	40960	320	640
5	10240	5120	320	160
6	10240	1280	10240	1280
7	640	160	40	320
8	2560	2560	640	640
9	10240	40960	640	5120
10	5120	40960	40960	40960
11	40960	10240	2560	20480
12	640	40	0	0



Abbreviations: ID; identification number, Lt; left nasopharyngeal samples, Rt; right

164 nasopharyngeal samples, NP; nasopharyngeal

166	The median viral titers of the left and right NP specimens at 3 minutes post-PVP-I
167	exposure were 3.4 log TCID ₅₀ /mL (IQR 1.8-4.4 log TCID ₅₀ /mL) and 2.7 log TCID ₅₀ /mL (IQR
168	2.0-3.9 log TCID ₅₀ /mL), respectively (P =0.433). The median Ct value of the N gene of the left
169	and right-side NP specimens at 3 minute post-PVP-I were 19.49 (IQR 16.95-23.10) and 19.58
170	(IQR 17.69-21.30), respectively (P=0.977). The median Ct value of the ORF1ab gene of the left
171	and right-side NP specimens at 3 minute post-PVP-I were 19.17 (IQR 15.81-24.87) and 20.86
172	(IQR 16.78-23.06), respectively (<i>P</i> =0.885).
173	At 4 hour post-PVP-I nasal spray, six of the 11 patients (54.5%) were observed to have
174	either the same titer or a minimal reduction of viral titers, and five patients had increased titers
175	from the samples collected at 3 minute post-PVP-I. The median viral titer at 3 minute post-PVP-
176	I exposure was 2.7 log TCID ₅₀ /mL (IQR 2.0-3.9 log TCID ₅₀ /mL), and the median viral titer at 4
177	hour post-PVP-I exposure was 2.8 log TCID ₅₀ /mL (IQR 2.2-3.9 log TCID ₅₀ /mL) (P =0.704). The
178	median Ct value of the N gene at 3 minute post-PVP-I exposure was 19.58 (IQR 17.69-21.30),
179	and the median Ct value of the N gene at 4 hour post-PVP-I exposure was 20.19 (IQR 18.01-
180	22.16) (P=0.339). The median Ct value of the ORF1ab gene at 3 minute post-PVP-I exposure
181	was 20.86 (IQR 16.78-23.06), and the median Ct value of the ORF1ab gene at 4 hour post-PVP-I
182	was 21.49 (IQR 16.69-23.38) (P=0.433).
183	
184	Table 4. Change in viral titers after 3 minute and 4 hour exposure to PVP-I as compared to the
185	baseline value from left NP specimens.

ID	≈ 10 fold	Within 4 fold reduction	No change or increase

	reduction		
1	3 min, Lt.	3 min, Rt.; 4h, Rt.	0
2	4h, Rt.	3 min, Lt.; 3 min, Rt.	0
3	0	3 min, Lt.; 3 min, Rt.; 4h, Rt.	0
4	0	3 min, Rt.; 4h, Rt.	3 min, Lt.
5	0	3 min, Lt.; 3 min, Lt; 4h, Rt.	0
6	0	3 min, Lt.; 4h, Rt.	3 min, Lt.
7	3 min Rt.	3 min, Lt.;4h, Rt.	
8	0	3 min, Rt.; 4h, Rt.	3 min, Lt.
9	0	3 min, Rt.; 4h, Rt.	3 min, Lt.
10	0	0	3 min, Lt.; 3 min, Lt.; 4h, Rt.
11	3 min, Rt.	3 min, Lt; 4h, Rt.	0
12	3 min, Lt.; 3 min,	0	0
	Rt.; 4h, Rt.		
		1	

186

187 Only one case (no. 12) showed viral titers decreased approximately ten folds. The rest 188 showed only within 1-4 fold reduction which could be due to sampling variation or weak PVP-I 189 anti-viral activity. Five cases even had increased viral titers after PVP-I exposure. Overall, the 190 decrease of viral titers is not rapid and not as much as shown by the in vitro test which is about 191 100 fold decrease 1 minute after PVP-I exposure. At 4 hour after PVP-I exposure, minimal or no 192 change in viral titer was demonstrated. Overall, the PVP-I did not demonstrate rapid and strong 193 virucidal activity as has been shown by the in vitro test.

195 Discussion

196 The TCID₅₀/mL of the 12 patients with culturable NP samples varied from 640 to 40,960, 197 which was not related to either disease severity or the onset of clinical symptoms when NP 198 swabs were taken. Because all cases recovered uneventfully, the initial values of $TCID_{50}/ml$ did 199 not predict the treatment outcome. However, the sample size was small and we did not plan to 200 study the relationship between the initial viral titers and disease severity or clinical outcome. 201 We found a median one-fold reduction of SARS-CoV-2 viral titer from nasopharyngeal 202 swabs at 3 minute post-PVP-I exposure in the left side of nasopharynx. This was in marked 203 contrast to in vitro studies that reported as much as a 100-fold reduction in viral titer [5]. At 4 204 hour post-exposure to 0.4% PVP-I nasal spray, the viral titer in the right side of nasopharynx was 205 unchanged from baseline in 10 cases. 206 Although the in vitro rapid activity of PVP-I against SARS-CoV-2 has been established 207 in several studies [5-7], evidence of in vivo activity in humans is limited. Two studies have 208 reported that PVP-I administration into the upper aerodigestive tract of COVID-19 patients was 209 associated with lower SARS-CoV-2 viral load and Ct values [12,13]. However, other studies 210 have not confirmed their results [14-16]. To measure potential reductions in viral shedding, we 211 believe that RT-PCR alone is insufficient and viral culture is needed. Using viral culture, PVP-I 212 administration probably reduced infectious viral titers in the upper respiratory tract of COVID-19 213 patients in two recent studies [20,21]. Friedland P et al demonstrated that 0.5% PVP-I nasal 214 spray was associated with a reduction of viral titers in five of the six study participants (83%) 215 five minutes after PVP-I application [20]. Seikai T et al revealed that gargling with PVP-I was

associated with significantly decreased viral titers at 60 minutes after PVP-I exposure [20].

217	We found that PVP-I nasal spray had poor in vivo efficacy in our study. This could be
218	explained by several factors including insufficient concentration, improper formulation and/or
219	amount of PVP-I, inadequate duration of exposure, inappropriate method of administration, and
220	mucociliary clearance of PVP-I from the nasal cavity [20]. We observed that 0.4% PVP-I nasal
221	spray did not change the Ct value of the N and ORF1ab segments and did not interfere with
222	PCR-mediated laboratory diagnosis of COVID-19. Finally, 0.4% PVP-I administered as a nasal
223	spray was safe and well-tolerated.
224	Our study had some limitations. First, this was a small, single-arm, pre- and post-
225	exposure pilot study, therefore, the study result may differ from larger-scale studies. Second, the
226	study participants were likely infected with the strain B.1.36.16 of SARS-CoV-2 that caused
227	infections in Thailand during the study period [22]. Our findings may not be generalizable to
228	other variants of SARS-CoV-2.
229	However, since the PVP-I has been shown to exhibit broad-spectrum, rapid virucidal
230	activity against various respiratory viruses by the in vitro tests, the finding of our study in
231	patients infected with SARS-CoV-2 should give warning against its use for prophylaxis in
232	ordinary people.
233	
234	Conclusions
235	The 0.4% PVP-I nasal spray had minimal virucidal activity in the nasopharynx of
236	infected patients. Hence, it is unlikely that this treatment would reduce airborne or droplet
237	transmission of COVID-19. Other preventive measures such as vaccination, face masking, and
238	personal protective equipment should be emphasized to limit COVID-19 transmission.
239	

240 Acknowledgements

241	The authors gratefully acknowledge Mrs. Sukanya Chanboonchuay for her assistance with
242	project management, Dr. Paraya Assanasen (ENT physician) for making the 0.4% PVP-I nasal
243	spray, Miss Suwimon Manopwisedjaroen, M.Sc. and Miss Chanya Srisaowakarn, M.Sc. for
244	microbiological laboratory assistance. The authors also thank the COVID-19 patient care team of
245	Samut Sakhon Hospital (Mr. Chaiyot Ra-ngubpai, Miss Punyanee Triamkan, Miss Laksamee
246	Suddee, Miss Kitima Limprasert and Mrs. Walaiporn Jaiaree) for providing patient information,
247	specimen collection, and patient observation during hospitalization.
248	
249	Declarations
250	Funding: This work was supported by the Health Systems Research Institute (Thailand),
251	Nonthaburi, Thailand; and, by the Faculty of Medicine Siriraj Hospital, Mahidol University,
252	Bangkok, Thailand. The funders had no role in study design, data collection and analysis,
253	decision to publish, or preparation of the manuscript.
254	
255	Competing Interests: The authors declared that the research was conducted in the absence of
256	any commercial or financial relationships that could be construed as a potential conflict of
257	interest.
258	
259	Ethical Approval: This study was approved by the Institutional Review Board of the Faculty of
260	Medicine Siriraj Hospital, Mahidol University (COA. 408/2020), and by the ethic committees of
261	Samut Sakhon Hospital (SKH REC 10/2564/V.1).
262	

263 References

- 264 1. COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19
- pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet 2022:S0140-
- **266** 6736(21)02796-3.
- 267 2. Badu K, Oyebola K, Zahouli JZB, Fagbamigbe AF, de Souza DK, et al. SARS-CoV-2 Viral
- 268 Shedding and Transmission Dynamics: Implications of WHO COVID-19 Discharge Guidelines.
- 269 Front Med (Lausanne) 2021;8:648660.
- 270 3. Casey-Bryars M, Griffin J, McAloon C, Byrne A, Madden J, Mc Evoy D, et al.
- 271 Presymptomatic transmission of SARS-CoV-2 infection: a secondary analysis using published
- data. BMJ Open 2021;11:e041240.
- 4. Pelletier JS, Miller D, Liang B, Capriotti JA. In vitro efficacy of a povidone-iodine 0.4% and
- dexamethasone 0.1% suspension against ocular pathogens. J Cataract Refract Surg 2011; 37:
- 275 763-766.
- 276 5. Anderson DE, Sivalingam V, Kang AEZ, Ananthanarayanan A, Arumugam H, Jenkins TM, et
- al. Povidone-iodine demonstrates rapid in vitro virucidal activity against SARS-CoV-2, the virus
- 278 causing COVID-19 disease. Infect Dis Ther 2020; 9: 669-675.
- 279 6. Bidra AS, Pelletier JS, Westover JB, Frank S, Brown SM, Tessema B. Rapid In-Vitro
- 280 Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Using
- 281 Povidone-Iodine Oral Antiseptic Rinse. J Prosthodont 2020; 29: 529-533.
- 282 7. Shet M, Hong R, Igo D, Cataldo M, Bhaskar S. In vitro evaluation of the virucidal activity of
- 283 different povidone-iodine formulations against murine and human coronaviruses. Infect Dis Ther
- **284** 2021; 10: 2777-2790.

- 285 8. Nagatake T, Ahmed K, Oishi K. Prevention of respiratory infections by povidone-iodine
- **286** gargle. Dermatology 2002; 204 Suppl 1: 32-36.
- 287 9. Ghaddara HA, Kumar JA, Cadnum JL, Ng-Wong YK, Donskey CJ. Efficacy of a povidone
- 288 iodine preparation in reducing nasal methicillin-resistant *Staphylococcus aureus* in colonized
- 289 patients. Am J Infect Control 2020; 48: 456-459.
- 290 10. Peng HM, Wang LC, Zhai JL, Weng XS, Feng B, Wang W. Effectiveness of preoperative
- decolonization with nasal povidone iodine in Chinese patients undergoing elective orthopedic
- surgery: a prospective cross-sectional study. Braz J Med Biol Res 2017; 51: e6736.
- 293 11. Krajewska Wojciechowska J, Krajewski W, Zub K, Zatoński T. Review of practical
- recommendations for otolaryngologists and head and neck surgeons during the COVID-19
- 295 pandemic. Auris Nasus Larynx 2020; 47: 544-558.
- 296 12. Seneviratne CJ, Balan P, Ko KKK, Udawatte NS, Lai D, Ng DHL, et al. Efficacy of
- commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in
 Singapore. Infection 2021; 49: 305-311.
- 299 13. Elzein R, Abdel-Sater F, Fakhreddine S, Hanna PA, Feghali R, Hamad H, et al. In vivo
- 300 evaluation of the virucidal efficacy of Chlorhexidine and Povidone-iodine mouthwashes against
- 301 salivary SARS-CoV-2. A randomized-controlled clinical trial. J Evid Based Dent Pract 2021; 21:
- **302** 101584.
- 303 14. Guenezan J, Garcia M, Strasters D, Jousselin C, Lévêque N, Frasca D, et al. Povidone iodine
- 304 mouthwash, gargle, and nasal spray to reduce nasopharyngeal viral load in patients with COVID-
- 19: A randomized clinical trial. JAMA Otolaryngol Head Neck Surg 2021; 147: 400-401.

- 306 15. Zarabanda D, Vukkadala N, Phillips KM, Qian ZJ, Mfuh KO, Hatter MJ, et al. The Effect of
- 307 Povidone-Iodine Nasal Spray on Nasopharyngeal SARS-CoV-2 Viral Load: A Randomized
- **308** Control Trial. Laryngoscope 2021: 10.1002/ lary.29935.
- 309 16. Ferrer MD, Barrueco ÁS, Martinez-Beneyto Y, Mateos-Moreno MV, Ausina-Márquez V,
- 310 García-Vázquez E, et al. Clinical evaluation of antiseptic mouth rinses to reduce salivary load of
- **311** SARS-CoV-2. Sci Rep 2021; 11: 24392.
- 312 17. A R, Wang H, Wang W, Tan W. Summary of the Detection Kits for SARS-CoV-2
- 313 Approved by the National Medical Products Administration of China and Their Application for
- **314** Diagnosis of COVID-19. Virol Sin 2020; 35: 699-712.
- 315 18. Sasaki M, Uemura K, Sato A, Toba S, Sanaki T, Maenaka K, et al. SARS-CoV-2 variants
- 316 with mutations at the S1/S2 cleavage site are generated in vitro during propagation in
- 317 TMPRSS2-deficient cells. PLoS Pathog 2021; 17: e1009233.
- **318** 19. Dhand NK, Khatkar MS. (2014). Statulator: An online statistical calculator. Sample Size
- 319 Calculator for Comparing Two Paired Proportions. Accessed 25 July 2022 at
- 320 http://statulator.com/SampleSize/ss2PP.html
- 321 20. Friedland P, Tucker S, Goodall S, Julander J, Meddenhall M, Molloy P, et al. In vivo
- 322 (human) and in vitro inactivation of SARS-CoV-2 with 0.5% povidone-iodine nasal spray. Aust
- **323** J Otolaryngol 2022; 5: 2.
- 324 21. Seikai T, Takada A, Hasebe A, Kajihara M, Okuya K, Sekiguchi Yamada T, et al. Gargling
- 325 with povidone iodine has a short-term inhibitory effect on SARS-CoV-2 in patients with
- 326 COVID-19. J Hosp Infect 2022: S0195-6701(22)00006-8.

- 327 22. Kunno J, Supawattanabodee B, Sumanasrethakul C, Wiriyasivaj B, Kuratong S,
- 328 Kaewchandee C. Comparison of Different Waves during the COVID-19 Pandemic:
- **329** Retrospective Descriptive Study in Thailand. Adv Prev Med 2021; 2021: 5807056.